NCT06186856 Epidemiological Data on Mast Cell Pathologies in France
| NCT ID | NCT06186856 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Imagine Institute |
| Condition | Mast Cell Disorder |
| Study Type | OBSERVATIONAL |
| Enrollment | 13,000 participants |
| Start Date | 2024-11-01 |
| Primary Completion | 2038-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 13,000 participants in total. It began in 2024-11-01 with a primary completion date of 2038-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Mast cell disorders constitute a heterogeneous group of diseases, including : * mastocytosis, i.e. cutaneous, indolent and severe forms of the disease, such as aggressive mastocytosis and mast cell leukemia) ; * mast cell-associated diseases such as mast cell activation syndrome (idiopathic, secondary or clonal), affecting both children and adults. No epidemiological data are currently available in France. In France, medical care of mast cell disorders is mainly provided by a rare disease network (CEREMAST), whose CRMR is located at the Necker Enfants Malades hospital in Paris. A total of 20 centers are located throughout France. Our aim is to use this network to study patients suffering from these diseases. The overall aim of the study is to improve the understanding, diagnosis, prognosis, recognition and management of patients with mastocytosis.
Eligibility Criteria
Inclusion Criteria: 1. Children from birth and adults of any age 2. With one of the following mast cell diseases: * Mastocytoses (cutaneous, systemic and sarcomas) Defined according to the WHO 2016 classification * Mast cell activation syndromes (idiopathic, secondary and clonal) * Other mast cell activation disorders (MCAD-NOS), Defined according to the Vienna classification * Pre-mastocytosis or MMC (1 to 2 criteria according to WHO 2016 classification). 3. Managed in France in a rare disease reference, constitutive or competence center (CEREMAST) with DGOS labelization. Exclusion Criteria: 1\. Opposition of the patient or his/her parents to participation in the study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06186856 clinical trial?
This trial is open to participants of all sexes, studying Mast Cell Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06186856 currently recruiting?
Yes, NCT06186856 is actively recruiting participants. Contact the research team at julien.rossignol@aphp.fr for enrollment information.
Where is the NCT06186856 trial being conducted?
This trial is being conducted at Amiens, France, Angers, France, Besançon, France, Caen, France and 11 additional locations.
Who is sponsoring the NCT06186856 clinical trial?
NCT06186856 is sponsored by Imagine Institute. The trial plans to enroll 13,000 participants.